: FDA approves Reata’s rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments

by | Feb 28, 2023 | Stock Market

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system. Reata’s RETA stock was halted in after-hours trading on Tuesday in advance of the FDA’s decision. The drug, omaveloxolone, which is now called Skyclarys,…

Article Attribution | Read More at Article Source

Share This